New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera

American Journal of Hematology

Volumn 90, Issue 8, 2015, Pages 683-685

  Tefferi, Ayalew ^a   Barbui, Tiziano ^b  

^a MAYO CLINIC   (United States)

^b PAPA GIOVANNI XXIII HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; HYDROXYUREA; JANUS KINASE 2; PHOSPHORUS; PIPOBROMAN; RUXOLITINIB; ENZYME INHIBITOR; FIBRINOLYTIC AGENT; JAK2 PROTEIN, HUMAN;

ARTERY THROMBOSIS; CYTOREDUCTIVE SURGERY; FIBROSIS; GENE MUTATION; HUMAN; LOW DRUG DOSE; NOTE; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TREATMENT CONTRAINDICATION; VEIN THROMBOSIS; AGE; AGED; BLOOD; DRUG ADMINISTRATION; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PATIENT SELECTION; RISK; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS;

AGE FACTORS; AGED; ASPIRIN; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYUREA; JANUS KINASE 2; MIDDLE AGED; MUTATION; PATIENT SELECTION; PHLEBOTOMY; POLYCYTHEMIA VERA; RISK; RISK ASSESSMENT; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS;

EID: 84937501320     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24037     Document Type: Note

References (20)

1. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015;90:162-173.
2. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368:22-33.
3. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-124.
4. Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23:132-143.
5. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136.
6. Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980. J Clin Oncol 2011;29:3907-3913.
7. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.
8. Vainchenker W, Constantinescu SN. A unique activating mutation in jak2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology Am Soc Hematol Educ Program 2005;195-200.
9. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014;123:1552-1555.
10. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International PrognosticScore of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012;120:5128-5133; quiz 5252.
11. Finazzi G, Carobbio A, Guglielmelli P, et al. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood 2014;124:2611-2612.
12. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients. Blood 2011;117:5857-5859.
13. Barbui T, Carobbio A, Rumi E, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 2014;124:3021-3023.
14. Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010;116:1205-1210; quiz 1387.
15. De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments. Haematologica 2008;93:372-380.
16. Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012;366:1959-1967.
17. Collaborative overview of randomised trials of antiplatelet therapy-III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308:235-246.
18. Dillinger JG, Sideris G, Henry P, et al. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia. Thromb Res 2012;129:91-94.
19. Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595-3603.
20. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015;372:426-435.